Company profile
Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05827614 | phase1 | terminated | 2023-03-24 | 2026-03-17 | Boundless Bio, Inc. | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications |
| NCT07408089 | phase1 | terminated | 2026-02-25 | 2026-07-28 | Boundless Bio, Inc. | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer |
| NCT06299761 | phase1 | terminated | 2024-03-28 | 2025-06-25 | Boundless Bio, Inc. | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications |
FDA applications (0)
No records yet.